Shandong Xinhua Pharmaceutical Gets Regulatory Nod for Cardiovascular Drug
MT Newswires Live
Oct 14, 2025
Shandong Xinhua Pharmaceutical (SHE:000756) obtained drug registration from China's medical products regulator for its bisoprolol fumarate tablets.
The drug is indicated for treating hypertension, angina and chronic heart failure, according to Tuesday filing with the Shenzhen bourse.
Shres of the pharmaceutical company rose 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.